OREX up +27.27% percent right now. $OREX High is at 4.88

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:34 PM

OREX up +27.27% percent right now. $OREX High is at 4.88 and the Low 4.04 with current volume of 5,295,252.

Recent News posted below.

OREX Orexigen Therapeutics Recent Headline News

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 9 mins ago

OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 34 mins ago

UCP: 11.96 (-1.83), JRJC: 6.16 (+0.65), NAVB: 1.02 (-0.20), SANW: 3.81 (+0.73), PLPM: 1.62 (+0.25), RYN: 28.85 (-5.05), INFU: 3.01 (-0.48), LIOX: 5.47 (+0.73), DY: 27.85 (-3.02), MTZ: 25.17 (-3.46), CGIX: 6.95 (+0.95), MUX: 1.25 (-0.16), OREX: 5.03 (+1.18), URRE: 2.60 (+0.66), ACHN: 12.61 (+2.50), REN: 2.86 (-0.75), MPO: 3.41 (+0.30), AKBA: 9.35 (-1.35), TRX: 1.02 (-0.20), PLNR: 7.60 (+1.20)

Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 2 hrs 6 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 5.03 (+1.18)

Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 2 hrs 42 mins ago

OREX: 5.03 (+1.18)

Orexigen ups earnings by 161% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:16AM CST

OREX: 5.03 (+1.18)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - Mon Nov 10, 9:33AM CST
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 5.03 (+1.18)

Orexigen Beats The Street On Milestone Payments
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 8:21AM CST

OREX: 5.03 (+1.18)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST

PT: 1.63 (+0.11), GPRO: 76.07 (-2.99), OREX: 5.03 (+1.18), GOGO: 18.10 (+1.46), JRJC: 6.16 (+0.65), UEC: 1.87 (+0.15), ACHN: 12.61 (+2.50), ARQL: 1.15 (+0.09), CMCM: 20.66 (+0.46), IBIO: 1.23 (+0.07), DF: 16.26 (+1.84)

Orexigen Therapeutics (OREX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:25AM CST

OREX: 5.03 (+1.18)

Orexigen Therapeutics beats by $0.22, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:08AM CST

OREX: 5.03 (+1.18)

Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 5.03 (+1.18)

Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 5.03 (+1.18), YY: 82.08 (+2.58), WDAY: 95.30 (+0.74), SSYS: 104.60 (+1.53), HKTV: 11.11 (+0.24)

Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.03 (+1.18)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.03 (+1.18), VVUS: 3.25 (-0.08), ARNA: 4.31 (+0.05)

Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 5.03 (+1.18)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.03 (+1.18), ARNA: 4.31 (+0.05)

Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 5.03 (+1.18)

Orexigen Therapeutics Has Substantial Upside For Bull Investors
L&F Capital Management - at Seeking Alpha - Wed Oct 29, 7:27AM CDT

OREX: 5.03 (+1.18)

Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 5.03 (+1.18), ARNA: 4.31 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mountain Living: Facing the Population Growth Crunch

Population Growth Reshaping U.S. Mountain Communities Living in a picturesque mountain town used to offer an idyllic escape from the hustle and bustle of city life. But now, even these scenic enclaves are feeling the squeeze from a wave of population growth that's hard to ignore. Mark Cromer tackles this head-on in his new Forum paper, 'The Long Goodnight of Rocky...

Heineken Hit with €111M Judgment—A Precedent Set

A Brew of Legal Consequences for Heineken If this isn't a financial wake-up call for the brewing giant, I don't know what is. In the latest twist of corporate accountability, the Amsterdam District Court has ordered Heineken and its Greek subsidiary, Athenian Brewery, to cough up a whopping €111 million. And we're not just talking pocket change—this ruling speaks...

Industrial Defender Boosts OT Cybersecurity Capabilities

OT Cybersecurity Takes a Step Forward So today, it’s all about this new roll-out by Industrial Defender. Just another tool shedding light in those dim corners of network security for critical infrastructure operators. Honestly, these folks have been at this for quite some time—talking 20 years uphill and still pushing. From Anomalies to Action Their latest magic?...

Laredo Oil Eyes Big Gains in Argentina's Oil Play

Argentina's Oil Play: Laredo Oil's Bold Venture Talk about shooting for the stars. Laredo Oil's second tête-à-tête with Santa Cruz Province's big wigs highlights their itch to rejuvenate Argentina's tired oil fields. For folks who know the nitty-gritty of oil, we're talking about the Golfo San Jorge Basin, a place where old dogs might learn new tricks thanks to that...

Trive Cashes Out on EarthLink, New Era with Family Offices

EarthLink's Changing Hands: What's the Real Deal? I tell you, the tech industry's like a game of hot potato, and right now, EarthLink's the spud getting tossed around. Trive Capital, the private equity force from Dallas, just wrapped up handing EarthLink over to a family office squad. That's WaveDivision Capital, The Pritzker Organization, and Stephens Capital Partners...

Radware Dominates SPARK Matrix™ for Bot Management

Why Radware Stands Out in Bot Management Radware has been making quite the splash in the tech world, now sitting pretty as the leader in QKS Group's SPARK Matrix™ for Bot Management in 2026. This isn't just some random pat on the back; it's a recognition of Radware's outstanding execution. Their innovative approach, especially in the realm of cloud application...

Abbott Shines in Q3 2026 with Strong Sales and EPS

Q3 2026: Abbott's Strategic Moves Pay Off When companies start tossing around terms like 'strong third-quarter results,' ears perk up—especially mine. Abbott (NYSE: ABT) gave us something to chew on with their Q3 2026 earnings, flexing a solid 14.5% reported sales growth. Hey, let’s not forget about the substantial comparable sales growth of 7.0%. They’re waving...

Rublev's Tennis Meet Boosts Inclusivity for Autism

Tennis Bridging Worlds in the Heart of Kazakhstan When Andrey Rublev, a powerhouse in the world of tennis, wields his racket for more than just a win, you know something special is brewing. During the Almaty Open ATP 250 tournament, he did exactly that, sharing the court not with rivals, but with ten spirited children from the Asyl Miras Autism Center. This heartwarming...

China Reaffirms Financial Opening-Up, Targets Global Investors

A New Stage in China's Financial Opening-Up China's making some serious waves in the financial seas this week, kicking off the Annual Conference of the Financial Street Forum 2026 in Beijing. The big guns from China's financial regulatory bodies are rolling out policies with one clear message: they’re serious about opening up. They're launching pilot initiatives like...

HR Path Expands with Payroll Experts Australia Deal

Expanding the HR Path in Australia When HR Path decided to buy up Payroll Experts Australia, it wasn't just another corporate power play. We're talking about a smart move to shore up some serious credibility in the HR consulting space down under. These guys aren't just dipping their toes in the Australian market; they're diving straight in with this acquisition, beefing...